logo
Eurofins Scientific SE: Director/PDMR Shareholding

Eurofins Scientific SE: Director/PDMR Shareholding

Yahoo15-05-2025

LUXEMBOURG, May 15, 2025--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1.
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Analytical Bioventures S.C.A (RCS B89265)23, Va Fleuri, L-1526 Luxembourg
2.
Reason for the notification
a)
Position / status
Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin
b)
Initial notification / amendment
Initial
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Eurofins Scientific S.E.
b)
LEI
529900JEHFM47DYY3S57
4.
Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Share
Identification code
ISIN: FR0014000MR3
b)
Nature of the transaction
Acquisition of shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
EUR 56.034800
2000
d)
Aggregated information
— Aggregated volume
2000
— Price
EUR 112,069.60
e)
Date of the transaction
2025-05-13
f)
Place of the transaction
XPAR
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1.
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Analytical Bioventures S.C.A (RCS B89265)23, Va Fleuri, L-1526 Luxembourg
2.
Reason for the notification
a)
Position / status
Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin
b)
Initial notification / amendment
Initial
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Eurofins Scientific S.E.
b)
LEI
529900JEHFM47DYY3S57
4.
Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Share
Identification code
ISIN: FR0014000MR3
b)
Nature of the transaction
Acquisition of shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
EUR 54.564900
4000
d)
Aggregated information
— Aggregated volume
4000
— Price
EUR 218,259.60
e)
Date of the transaction
2025-05-14
f)
Place of the transaction
XPAR
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With ca. 63,000 staff across a network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods.Eurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250515548046/en/
Contacts
For more information, please visit www.eurofins.com or contact:
Investor RelationsEurofins Scientific SEPhone: +32 2 766 1620E-mail: ir@sc.eurofinseu.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Infobip Named Among Top 75 in Fortune's Europe's Most Innovative Companies 2025
Infobip Named Among Top 75 in Fortune's Europe's Most Innovative Companies 2025

Business Wire

time2 hours ago

  • Business Wire

Infobip Named Among Top 75 in Fortune's Europe's Most Innovative Companies 2025

VODNJAN, Croatia--(BUSINESS WIRE)--Global communications platform Infobip has been recognized among the top 75 companies in Fortune's inaugural ranking of Europe's Most Innovative Companies for 2025. It holds the position of number 68, placing it in the top 25% of all listed companies. This distinction reflects Infobip's ongoing commitment to advancing Europe's IT sector and digital infrastructure through cutting-edge innovation. The first Fortune Europe's Most Innovative Companies list, created in collaboration with Statista, evaluated 300 companies from 21 countries and 16 industries based on innovation culture, product development, and process improvements. Infobip is at the forefront of Europe's digital transformation. Infobip participates in the IPCEI-CIS project, which aims to build the next-generation global communications platform, thereby reinforcing Europe's competitiveness in the tech sector. Infobip's involvement in the IPCEI-CIS project, along with partnerships with Deutsche Telekom AG, NVIDIA, Telefónica, and others, demonstrates its continuous commitment to progress with innovation. Silvio Kutić, CEO at Infobip, said: 'Being recognised among Europe's Most Innovative companies by Fortune highlights our ongoing commitment to the cutting-edge. At Infobip, we foster an environment that values experimentation and collaboration, viewing failure as a stepping stone to innovation, which has enabled us to redefine omnichannel communications. As companies strive to enhance their engagement strategies, we frequently play the role of innovation executor, helping businesses across industries advance their conversational adoption journey and keep pace with AI innovation.' Infobip's technology powers customer engagement for leading brands, from enabling WhatsApp ride-booking for Uber in India to deploying advanced AI assistants for European fintech and retail leaders. The company's omnichannel solutions help businesses worldwide deliver secure, personalized, and seamless customer experiences. Recent projects with customers like NEXT, Digitaleo, and AXA showcase the company's innovative work with AI and RCS to elevate their engagement strategies. Infobip also drives industry dialogue through initiatives like the annual SHIFT Conference, which brings together developers and tech executives to explore the future of AI and digital transformation. This year's event will be held from September 14-16 in Zadar, Croatia, with a focus on AI's impact on software development and creativity. Grethe Schepers, Lists Director, Europe at Fortune, said: 'This list isn't just about who's ahead today—it's a spotlight on the bold thinkers across Europe who are redefining industries from the inside out. Innovation isn't just a buzzword here; it is a core and defining strength for Europe.' See Europe's Most Innovative Companies List 2025 here: About Infobip Infobip is a global cloud communications platform that enables businesses to build connected experiences across all stages of the customer journey. Accessed through a single platform, Infobip's omnichannel engagement, identity, user authentication and contact center solutions help businesses and partners overcome the complexity of consumer communications to grow business and increase loyalty.

ONWARD Medical Announces Results of its Annual General Meeting of Shareholders
ONWARD Medical Announces Results of its Annual General Meeting of Shareholders

Yahoo

time17 hours ago

  • Yahoo

ONWARD Medical Announces Results of its Annual General Meeting of Shareholders

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Shareholders approve all proposed resolutions EINDHOVEN, The Netherlands, June 11, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury and other movement disabilities, today announces that that all proposed resolutions at its Annual General Meeting of Shareholders (AGM) were duly passed. The meeting was held this afternoon in Amsterdam, the Netherlands at 4:00PM CET. Full details of the resolutions approved during the AGM can be found on the Company's Investor Relations website. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury (SCI) and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company's ARC-EX System is cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM with and without an implanted brain-computer interface (BCI). Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). To learn more about ONWARD Medical's commitment to partnering with the spinal cord injury community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit To be kept informed about the Company's technologies, research studies, and the availability of therapies in your area, please complete this webform. For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Disclaimer Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited. ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive). Other Investigational Products: All other ONWARD Medical devices and therapies including ARC-IM and ARC-BCI are investigational and not available for commercial use.

Twilio and Orange to Bring Secure and Interactive RCS Messaging to Businesses in France
Twilio and Orange to Bring Secure and Interactive RCS Messaging to Businesses in France

Business Wire

timea day ago

  • Business Wire

Twilio and Orange to Bring Secure and Interactive RCS Messaging to Businesses in France

LONDON--(BUSINESS WIRE)--Today at Transform London, Twilio announced that it is partnering with Orange, one of the world's leading telecommunications operators, to scale the use of RCS Business Messaging across France. This partnership represents a major milestone in the evolution of mobile messaging in the country, providing French and international businesses with a rich, interactive, and secure communications experience directly in their messaging app. RCS already covers over 70% of the mobile base in France as of June 1, 2025 — representing more than 45 million smartphones — and is projected to reach 85% by the end of the year. In this context, Orange has chosen Twilio's globally recognized expertise to support the deployment of this next-generation messaging solution. Trust and transparency have become central to customer expectations. RCS fully addresses these priorities by enhancing the credibility and impact of brand communications. According to Twilio's 2025 State of Customer Engagement Report, 3 in 4 businesses plan to invest in RCS messaging this year and 81% of consumers prefer RCS over traditional SMS. 'We are delighted to work with Twilio, a global technology leader that is helping to drive the transformation of digital communications worldwide. This partnership will help to accelerate the deployment of RCS Business messaging in France. With 70% of smartphones now able to send and receive RCS messages according to our latest figures, it is set to become the new standard for mobile messaging. RCS Business Messaging offers improved security for brands, which creates a trusted relationship with customers while enhancing brand credibility. This in turn will lead to greater response rates and improved customer engagement,' said Amelia Newsom Davis, Director Payment, Messaging and Identity at Orange France. As the natural evolution of SMS, the RCS protocol is now available across both Android and iOS devices. It supports enriched exchanges and an interactive experience with features like images, carousels, actionable buttons, and detailed performance tracking. By partnering with Twilio, Orange will enable businesses in France to drive stronger customer engagement while maximizing message reach. For the remaining portion of the mobile base not yet covered by RCS, Twilio ensures seamless fallback to SMS, guaranteeing continuous service for all users. 'Customers in France expect more than just messages, they want secure, engaging interactions they can trust. RCS gives businesses a powerful way to deliver rich, branded conversations directly in the native messaging app, with verified sender identity. We share a common vision with Orange: to make communication more human, more dynamic, relevant and amazing. This partnership will enable businesses to boost engagement, efficiency, and trust, while offering a more dynamic experience that truly leaves an impression on customers. And in a landscape filled with plenty of competing digital noise, RCS represents an opportunity to stand out from the crowd,' said Tony Cheema, Vice President, EMEA, Communications at Twilio. For more information about Twilio's RCS services and how they can help your brand deliver reliable, personalized communications at scale, please visit About Twilio Today's leading companies trust Twilio's Customer Engagement Platform (CEP) to build direct, personalized relationships with their customers everywhere in the world. Twilio enables companies to use communications and data to add intelligence and security to every step of the customer journey, from sales to marketing to growth, customer service and many more engagement use cases in a flexible, programmatic way. Across 180 countries, millions of developers and hundreds of thousands of businesses use Twilio to create magical experiences for their customers. For more information about Twilio (NYSE: TWLO), visit:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store